The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.25
Bid: 19.00
Ask: 19.50
Change: -0.25 (-1.28%)
Spread: 0.50 (2.632%)
Open: 19.50
High: 19.50
Low: 18.50
Prev. Close: 19.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

2 Nov 2005 09:41

Angle PLC02 November 2005 NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIALRESPONSIBILITY OR CONNECTED PERSONS This form is intended for use by an issuer to make a RIS notification requiredby DR 3.1.4R(1). Please complete all relevant boxes should in block capital letters. 1. Name of the issuerAngle Plc 2. State whether the notification relates to (i) a transaction notified inaccordance with DR 3.1.4R(1)(a); or(ii) DR 3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (asextended by section 328) of the Companies Act 1985; or(iii) both (i) and (ii)Both 3. Name of person discharging managerial responsibilities/directorIan Griffiths 4. State whether notification relates to a person connected with a persondischarging managerial responsibilities/director named in 3 and identify theconnected personN/a 5. Indicate whether the notification is in respect of a holding of the personreferred to in 3 or 4 above or in respect of a non-beneficial interestas in 3 above6. Description of shares (including class), debentures or derivatives orfinancial instruments relating to sharesOrdinary shares of 10p each 7. Name of registered shareholders(s) and, if more than one, the number ofshares held by each of themIan Griffiths 8 State the nature of the transactionPurchase of Ordinary Shares 9. Number of shares, debentures or financial instruments relating to sharesacquired8932 10. Percentage of issued class acquired (treasury shares of that class shouldnot be taken into account when calculating percentage)0.05% 11. Number of shares, debentures or financial instruments relating to sharesdisposedn/a 12. Percentage of issued class disposed (treasury shares of that class shouldnot be taken into account when calculating percentage)n/a 13. Price per share or value of transaction£1.115 per share 14. Date and place of transaction1 November 2005 15. Total holding following notification and total percentage holding followingnotification (any treasury shares should not be taken into account whencalculating percentage)529,546 shares. 3.17% 16. Date issuer informed of transaction1 November 2005 If a person discharging managerial responsibilities has been granted options bythe issuer complete the following boxes 17 Date of grant .................................... 18. Period during which or date on which it can be exercised .................................... 19. Total amount paid (if any) for grant of the option .................................... 20. Description of shares or debentures involved (class and number) ........................................................................ 21. Exercise price (if fixed at time of grant) or indication that price is to befixed at the time of exercise .................................... 22. Total number of shares or debentures over which options held followingnotification .................................... 23. Any additional information .................................... 24. Name of contact and telephone number for queriesIan Griffiths 01483 295830 Name and signature of duly authorised officer of issuer responsible for makingnotification .................................... Date of notification2 November 2005 END (1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.(2) An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8,13, 14, 16, 23 and 24.(3) An issuer making a notification in respect of options granted to a director /person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.(4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery
5th Dec 20237:00 amRNSANGLE launches Portrait+ CTC kit at SABCS
9th Nov 20237:00 amRNSLaunch of PD-L1 test to support cancer studies
9th Nov 20237:00 amRNSTrading and business update
25th Oct 20237:00 amRNSSupporting characterisation of CTCs in HNSCC
3rd Oct 20237:00 amRNSParsortix outperforms standard for DTC harvest
29th Sep 20237:00 amRNSParsortix system showcased at ACTC conference
7th Sep 20237:00 amRNSInterim Results for the period ended 30 June 2023
4th Sep 20237:00 amRNSANGLE launch of Portrait Flex assay
15th Aug 20237:00 amRNSANGLE notice of interim results
28th Jun 20234:54 pmRNSResult of 2023 Annual General Meeting
27th Jun 202312:24 pmRNSStandard form for notification of major holdings
5th Jun 20237:00 amRNSANGLE announces senior management appointments
25th May 20237:00 amRNSPharma services contract with Artios Pharma
22nd May 20237:00 amRNSBoard change - appointment of new Chairman
21st Apr 202312:04 pmRNSANGLE presentation via Investor Meet Company
21st Apr 20237:00 amRNSResults for the year ended 31 December 2022
19th Apr 20237:00 amRNSANGLE announces partnership with BioView
17th Apr 20237:00 amRNSANGLE Parsortix poster presented at AACR 2023
13th Apr 20237:00 amRNSPharma Services Contract with Crescendo Biologics
3rd Apr 20237:00 amRNSNotice of Preliminary Results and Webcast
10th Mar 20237:00 amRNSIssue of LTIP Options and Share Options
9th Mar 20233:03 pmRNSHolding(s) in Company
9th Feb 20232:44 pmRNSDirector/PDMR shareholding
19th Jan 20237:00 amRNSAppointment of Non-Executive Director
11th Jan 20235:20 pmRNSHolding(s) in Company
10th Jan 20236:20 pmRNSHolding(s) in Company
6th Jan 202311:05 amRNSSecond Price Monitoring Extn
6th Jan 202311:00 amRNSPrice Monitoring Extension
5th Jan 20239:05 amRNSSecond Price Monitoring Extn
5th Jan 20239:00 amRNSPrice Monitoring Extension
5th Jan 20237:01 amRNSAppointment of Non-Executive Director
5th Jan 20237:00 amRNSBusiness Update
12th Dec 20227:00 amRNSTwo Parsortix posters presented at SABCS
2nd Dec 20225:30 pmRNSIssue of Equity
2nd Nov 20227:00 amRNSMultiple downstream analysis techniques for CTCs
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20227:00 amRNSParsortix poster presented at ISLB meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.